Curcumin and genistein: The combined effects on disease-associated CFTR mutants and their clinical implications

Yoshiro Sohma, Ying Chun Yu, Tzyh Chang Hwang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Genistein and curcumin are major components of Asian foods, soybean and curry turmeric respectively. These compounds have been intensively investigated for their chemical and biological features conferring their anti-cancer activity. Genistein and curcumin have also been investigated for their potentiation effects on disease-associated CFTR mutants such as ΔF508 and G551D. Recently, we investigated the combined effect of genistein and curcumin on G551D-CFTR, which exhibits gating defects without abnormalities in protein synthesis or trafficking using the patch-clamp technique. We found that genistein and curcumin showed additive effects on their potentiation of G551D-CFTR in high concentration range and also, more importantly, showed a significant synergistic effect in their minimum concentration ranges. These results are consistent with the idea that multiple mechanisms are involved in the action of these CFTR potentiators. In this review, we revisit the pharmacology of genistein and curcumin on CFTR and also propose new pharmaceutical implications of combined use of these compounds in the development of drugs for CF pharmacotherapy.

Original languageEnglish
Pages (from-to)3521-3528
Number of pages8
JournalCurrent Pharmaceutical Design
Volume19
Issue number19
DOIs
Publication statusPublished - 2013

Fingerprint

Curcumin
Genistein
Curcuma
Patch-Clamp Techniques
Soybeans
Pharmaceutical Preparations
Pharmacology
Drug Therapy
Food
Neoplasms
Proteins

Keywords

  • Additive effect
  • G551D
  • Synergistic effect

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Curcumin and genistein : The combined effects on disease-associated CFTR mutants and their clinical implications. / Sohma, Yoshiro; Yu, Ying Chun; Hwang, Tzyh Chang.

In: Current Pharmaceutical Design, Vol. 19, No. 19, 2013, p. 3521-3528.

Research output: Contribution to journalArticle

Sohma, Yoshiro ; Yu, Ying Chun ; Hwang, Tzyh Chang. / Curcumin and genistein : The combined effects on disease-associated CFTR mutants and their clinical implications. In: Current Pharmaceutical Design. 2013 ; Vol. 19, No. 19. pp. 3521-3528.
@article{15633681773948779d1a373cd25f6955,
title = "Curcumin and genistein: The combined effects on disease-associated CFTR mutants and their clinical implications",
abstract = "Genistein and curcumin are major components of Asian foods, soybean and curry turmeric respectively. These compounds have been intensively investigated for their chemical and biological features conferring their anti-cancer activity. Genistein and curcumin have also been investigated for their potentiation effects on disease-associated CFTR mutants such as ΔF508 and G551D. Recently, we investigated the combined effect of genistein and curcumin on G551D-CFTR, which exhibits gating defects without abnormalities in protein synthesis or trafficking using the patch-clamp technique. We found that genistein and curcumin showed additive effects on their potentiation of G551D-CFTR in high concentration range and also, more importantly, showed a significant synergistic effect in their minimum concentration ranges. These results are consistent with the idea that multiple mechanisms are involved in the action of these CFTR potentiators. In this review, we revisit the pharmacology of genistein and curcumin on CFTR and also propose new pharmaceutical implications of combined use of these compounds in the development of drugs for CF pharmacotherapy.",
keywords = "Additive effect, G551D, Synergistic effect",
author = "Yoshiro Sohma and Yu, {Ying Chun} and Hwang, {Tzyh Chang}",
year = "2013",
doi = "10.2174/13816128113199990320",
language = "English",
volume = "19",
pages = "3521--3528",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "19",

}

TY - JOUR

T1 - Curcumin and genistein

T2 - The combined effects on disease-associated CFTR mutants and their clinical implications

AU - Sohma, Yoshiro

AU - Yu, Ying Chun

AU - Hwang, Tzyh Chang

PY - 2013

Y1 - 2013

N2 - Genistein and curcumin are major components of Asian foods, soybean and curry turmeric respectively. These compounds have been intensively investigated for their chemical and biological features conferring their anti-cancer activity. Genistein and curcumin have also been investigated for their potentiation effects on disease-associated CFTR mutants such as ΔF508 and G551D. Recently, we investigated the combined effect of genistein and curcumin on G551D-CFTR, which exhibits gating defects without abnormalities in protein synthesis or trafficking using the patch-clamp technique. We found that genistein and curcumin showed additive effects on their potentiation of G551D-CFTR in high concentration range and also, more importantly, showed a significant synergistic effect in their minimum concentration ranges. These results are consistent with the idea that multiple mechanisms are involved in the action of these CFTR potentiators. In this review, we revisit the pharmacology of genistein and curcumin on CFTR and also propose new pharmaceutical implications of combined use of these compounds in the development of drugs for CF pharmacotherapy.

AB - Genistein and curcumin are major components of Asian foods, soybean and curry turmeric respectively. These compounds have been intensively investigated for their chemical and biological features conferring their anti-cancer activity. Genistein and curcumin have also been investigated for their potentiation effects on disease-associated CFTR mutants such as ΔF508 and G551D. Recently, we investigated the combined effect of genistein and curcumin on G551D-CFTR, which exhibits gating defects without abnormalities in protein synthesis or trafficking using the patch-clamp technique. We found that genistein and curcumin showed additive effects on their potentiation of G551D-CFTR in high concentration range and also, more importantly, showed a significant synergistic effect in their minimum concentration ranges. These results are consistent with the idea that multiple mechanisms are involved in the action of these CFTR potentiators. In this review, we revisit the pharmacology of genistein and curcumin on CFTR and also propose new pharmaceutical implications of combined use of these compounds in the development of drugs for CF pharmacotherapy.

KW - Additive effect

KW - G551D

KW - Synergistic effect

UR - http://www.scopus.com/inward/record.url?scp=84887394805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887394805&partnerID=8YFLogxK

U2 - 10.2174/13816128113199990320

DO - 10.2174/13816128113199990320

M3 - Article

C2 - 23331029

AN - SCOPUS:84887394805

VL - 19

SP - 3521

EP - 3528

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 19

ER -